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ORIGINAL ARTICLE
Association of Improvement in Pain With
Therapeutic Response as Determined by
Individual Improvement Criteria in Patients
With Rheumatoid Arthritis
EVA C. SCHARBATKE,1 FRANK BEHRENS,2 MARC SCHMALZING,1 MICHAELA KOEHM,2
GERD GREGER,3 HOLGER GNANN,4 HARALD BURKHARDT,2 AND HANS-PETER TONY1
Objective. To use statistical methods to establish a threshold for individual response in patient-reported outcomes
(PROs) in patients with rheumatoid arthritis.
Methods. We used an analysis of variance model in patients on stable therapy (discovery cohort) to establish critical dif-
ferences (dcrit) for the minimum change associated with a significant individual patient response (beyond normal variation)
in the PRO measures of pain (0–10), fatigue (0–10), and function (Funktionsfragebogen Hannover questionnaire; 0–100).
We then evaluated PRO responses in patients initiating adalimumab in a noninterventional study (treatment cohort).
Results. In the discovery cohort (n 5 700), PROs showed excellent long-term retest reliability. The minimum change
that exceeded random fluctuation was conservatively determined to be 3 points for pain, 4 points for fatigue, and 16
points for function. In the treatment cohort (n 5 2,788), 1,483 patients (53.2%) achieved a significant individual thera-
peutic response as assessed by Disease Activity Score in 28 joints (DAS28)–dcrit (‡1.8 points) after 12 months of ada-
limumab treatment; 68.5% of patients with a DAS28-dcrit response achieved a significant improvement in pain,
whereas approximately 40% achieved significant improvements in fatigue or function. Significant improvements in all
3 PROs occurred in 22.7% of patients; 22.8% did not have any significant PRO responses. In contrast, significant
improvements in all 3 PROs occurred in only 4.4% of 1,305 patients who did not achieve a DAS28-dcrit response at
month 12, and 59.1% did not achieve any significant PRO responses.
Conclusion. The establishment of critical differences in PROs distinguishes true responses from random variation and
provides insights into appropriate patient management.
INTRODUCTION
Patient-reported outcomes (PROs) provide an important
perspective on the patient’s perceptions of his or her clini-
cal well-being. These outcomes, including patient global
disease assessment, pain, function, and fatigue can be
used to accurately discriminate between active treatment
and placebo in patients with rheumatoid arthritis (RA)
and may be more sensitive to treatment effectiveness than
objective clinical assessments (1). Furthermore, certain
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PROs, including patient global disease assessment and
functional questionnaires, are more closely related to
clinical outcomes than objective assessments of disease
activity such as laboratory markers, joint counts, or
radiographs (2). In multiple studies, patient-reported
functional status has been shown to be the most signifi-
cant predictor of mortality in patients with RA, out-
weighing clinical or laboratory assessments such as joint
counts, rheumatoid factor seropositivity, or erythrocyte
sedimentation rate (ESR) (reviewed by Pincus et al [2]).
Because of the importance of PROs in evaluating treat-
ment response and predicting long-term outcomes, we uti-
lized data from a large German noninterventional study of
patients with RA receiving adalimumab during routine
clinical care (3) to examine the association between PROs
and the Disease Activity Score in 28 joints (DAS28), a fre-
quently used measure of disease activity that includes 3
objective components (swollen joint count, tender joint
count, and ESR) and 1 subjective component (patient global
assessment of health or disease activity [PGA]). In a previ-
ous publication, we reported on the use of statistical mea-
sures to determine a critical difference (dcrit) for the
minimum change associated with a significant individual
patient response in disease activity as assessed by the
DAS28 (4). This method is fundamentally different from
those used to evaluate minimum clinically important dif-
ferences (MCIDs). The goal of MCID assessments is to iden-
tify the smallest change perceived as beneficial by patients
(5), whereas the dcrit method is based on the premise
that significant individual responses should, at minimum,
result in changes that exceed within-subject, measurement-
associated variability over periods of time relevant to a clin-
ical setting (4). In this respect, the dcrit method is similar to
assessments of the smallest detectable difference (SDD) (6)
or the reliable change index (7). However, these latter
assessments are usually based on reliability constants
derived from measurements made over a short period of
time, rather than over a period of months to a year, a time
frame that is more relevant to assessment of RA.
Here we utilize the dcrit statistical method to establish
criteria for significant responses in the PROs of pain,
fatigue, and function. Our study provides key insights
into the magnitude of change required for a significant
PRO response and into the association between therapeu-
tic response and significant improvements in PROs.
PATIENTS AND METHODS
Patients. This study utilized 2 German patient cohorts:
a discovery cohort including only patients with stable dis-
ease and on stable therapy, and a treatment cohort. Both
patient cohorts were derived from multicenter, nonin-
terventional studies of patients with active RA initiating
treatment with adalimumab, a tumor necrosis factor inhib-
itor (TNFi).
Patients in the discovery cohort were enrolled in a 2-
year noninterventional study (NCT01077258), which has
been previously described (3), and were seen between
April 2004 and February 2013. Only patients with stable
therapy (no changes in therapeutic agents or corticoste-
roid dose) between month 12 and month 24 of the study
were included in discovery cohort analyses. In addition,
discovery cohort patients were required to have a com-
plete data set (data at months 12, 18, and 24) for 1 or more
PRO variable. For each PRO evaluation, analyses were
limited to patients in the discovery cohort with a complete
data set for the PRO being evaluated. Data from months
12, 18, and 24 were used to assess long-term test–retest
reliability of PRO measures.
Patients in the treatment cohort were enrolled in a 5-
year noninterventional study (NCT01078090) with a simi-
lar design to the 2-year study. These patients were seen
between April 2003 and March 2013. To be included in
the noninterventional studies, patients were required to
have a diagnosis of RA, active disease, a clinical
Significance & Innovations
 We used statistical methods to determine a critical
difference (dcrit) required for significant individ-
ual patient responses in patient-reported out-
comes (PROs) in patients initiating therapy with
adalimumab, a tumor necrosis factor inhibitor,
and to evaluate correlations between PROs (pain,
fatigue, and function) and objective measures of
disease activity, such as the Disease Activity
Score in 28 joints (DAS28).
 Of the 3 PROs evaluated, pain showed the highest
correlation with DAS28 and fatigue showed the
lowest. Of patients with an objective therapeutic
response as defined by DAS28-dcrit at month 12,
68.5% showed a significant individual improve-
ment in pain and approximately 40% showed
improvements in fatigue and function.
 Compared with patients who had an objective
DAS28 response to therapy, patients who did not
experience an objective DAS28 response to ther-
apy were far less likely to achieve significant
improvements in PROs.
 Our data supply additional support for the rele-
vance of statistically determined individual improve-
ment criteria in clinical practice and provide insights
into appropriate patient management and typical
outcomes during adalimumab therapy that may
be useful in managing treatment expectations.
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indication for treatment with a TNFi, and no contra-
indications to TNFi therapy. All patients were informed of
the study objectives and gave written consent for the
anonymous use of their personal data in statistical analy-
ses. Because of the noninterventional nature of this study,
ethics approval was not required by German law.
Patients in the treatment cohort who were included in
the analyses reported here were required to have data for
DAS28, pain, function, and fatigue at baseline and month
12. Patients receiving additional biologic therapies and
those who had received previous therapy with adalimu-
mab were excluded from these analyses.
Evaluations of disease activity and PROs. Disease
activity was assessed by the DAS28, a validated instru-
ment in which higher scores indicate greater disease activ-
ity (8,9). The self-administered Funktionsfragebogen
Hannover (FFbH) patient questionnaire was used to assess
patient function on a scale of 0 (total loss of functional
capacity) to 100 (maximal functional capacity) units (10);
the FFbH score indicates the remaining percentage of
function. The FFbH has been validated in patients with
RA and is comparable to the Health Assessment Question-
naire Disability Index (11); an English translation has been
published by Westhoff et al (12). Pain and fatigue were
evaluated by use of 11-point scales in which a score of 0
represented the best possible status and a score of 10 indi-
cated the worst possible status. PGA was not evaluated as
a PRO, as our goal was to examine the association between
PROs and DAS28. Because PGA is one of the measures
used to calculate DAS28, the use of this PRO would have
confounded the analyses. However, PGA and physician
global assessment of disease activity (MDGA) were
included in evaluations of correlations between PROs and
other measures of disease activity. PGA and MDGA were
assessed on 11-point scales, in which a score of 0 repre-
sented the best possible status and a score of 10 indicated
the worst possible status.
Statistical analyses. Summary statistics are presented
for demographic and disease characteristics. Missing data
were not imputed. The method for determining the long-
term reliability and critical difference (e.g., the minimum
change that can be reliably discriminated from random
variations) in PROs was based on evaluations of intra-
individual variation in patients who were treated for 2
years, with stable therapy from months 12 through 24, as
has been described previously (4). Briefly, we adapted the
method of Lienert and Raatz (13) to determine a critical
difference based on the 1-sided 5% z-value of the normal
distribution in patients on stable therapy. The 1-sided crit-
ical difference (i.e., dcrit value) was used to define thera-
peutic response (14), as only reductions in disease activity
are relevant to defining a response. Dcrit values for
increases in disease activity were not evaluated. The
1-sided dcrit values for reductions in disease activity were
then used to evaluate responses in patients initiating ada-
limumab therapy. Patients who showed an improvement
that equaled or exceeded the 1-sided dcrit value were con-
sidered to have experienced a statistically significant
improvement that could not be explained by intraindividual
variation and were classified as responders for that outcome.
Patients with changes less than the dcrit value or with in-
creases in disease activity were classified as nonresponders
for that outcome. The method of Lienert and Ratz (13) is
based on within-subject variance rather than between-
subject variance.
Pearson’s correlation coefficients were used to evalu-
ate the association between PROs and other disease
activity assessments (1 indicates a perfect positive linear
relationship and 21 indicates a perfect negative linear
relationship).
RESULTS
Determination of the critical difference in PROs. The
discovery cohort (n 5 700) consisted of patients who had
received stable RA therapy (no changes in therapeutic
agents or corticosteroid dose) between months 12 and 24
after initiating adalimumab therapy in a noninterventional
study. This requirement for stable treatment allowed intra-
individual fluctuations in outcomes to be distinguished
from responses due to alterations in therapy. Demographic
and disease characteristics of the patients in the discovery
cohort are presented in Table 1 for both baseline (initia-
tion of adalimumab treatment) and month 12 (entry into
the discovery cohort on the basis of stable disease and
therapy). Patients had a mean disease duration of 11.4
years and a mean age of 54.3 years at baseline. After 12
months of adalimumab treatment, patients in the discov-
ery cohort had low to moderate disease activity (mean
DAS28 score 3.3). The discovery cohort maintained a
mean 6 SD DAS28 of 3.3 6 1.4 at month 18 and month 24,
thereby achieving the crucial methodologic requirement
of constant disease activity under fixed therapeutic
regimens.
To establish the minimum level of change required to
reliably distinguish relevant changes in PRO scores from
random variations, we determined the retest reliability of
each PRO (pain, fatigue, and function) in the discovery
cohort (Table 2) based on data from months 12, 18, and 24.
Function had the highest retest reliability (0.942), but all
of the disease activity measures, including the PROs,
showed relatively high values (.0.75).
Because responder analyses utilize individual changes
rather than mean changes in a population, this method
cannot accommodate fractional changes for integer-based
scales (e.g., pain and fatigue). Accordingly, the values
were rounded up to the nearest higher integer for
responder analyses. On the basis of the calculated values,
we conservatively determined that an individual improve-
ment would require a decrease of $3 points for a thera-
peutic response in pain, a decrease of $4 points for a
response in fatigue, and an increase of $16 points for a
therapeutic response in function (FFbH). As in the previ-
ous study, we used a conservative DAS28-dcrit value of 1.8
to indicate a therapeutic response in disease activity, as
our previous research showed that this value could be
applied to all patients independent of their individual dis-
ease characteristics (4).
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Evaluation of PRO responses in patients achieving a
DAS28-dcrit response. Having established dcrit values that
exceeded the threshold of random variation using data
from a discovery cohort with stable disease activity and
treatment, we then applied these values to a population of
patients with active RA. The applicability of data derived
from a discovery cohort to a population with active dis-
ease was validated for the DAS28-dcrit in our previous
publication (4). Statistically significant PRO responses
were evaluated in a treatment cohort of 2,788 German
patients initiating treatment with adalimumab in a nonin-
terventional study. Compared with the discovery cohort,
the treatment cohort had similar mean demographic char-
acteristics at baseline (prior to adalimumab treatment ini-
tiation), but increased signs of disease activity as
indicated by mean DAS28, swollen and tender joint
counts, and inflammatory markers (Table 1). At month 12,
1,483 patients (53.2%) in the treatment cohort achieved a
significant DAS28 response (improvement of at least 1.8
points from baseline), and 1,305 patients (46.8%) did not
achieve a DAS28-dcrit response.
To provide insights into the association between PROs
and objective responses of disease activity, we evaluated
statistically significant PRO responses at month 12 in the
subset of patients who achieved a therapeutic response as
determined by a change in DAS28 of $1.8 from baseline at
month 12. Of the 1,483 patients with a DAS28-dcrit
response, 1,016 (68.5%) also showed a significant
improvement in pain, 571 (38.5%) showed a significant
improvement in fatigue, and 623 (42.0%) showed a signifi-
cant improvement in function (Figure 1A and Figure 2).
Overall, 1,145 (77.2%) reported a significant improvement
in at least 1 PRO (pain, fatigue, or function), 338 (22.8%)
did not achieve a significant PRO response for any out-
come, and 336 (22.7%) showed improvement in all 3
PROs. In patients with only 1 PRO response, pain
accounted for the vast majority of responses (20.9% versus
2.4% for fatigue and 4.8% for function). Similarly, in
patients with 2 PRO responses, pain in combination with
fatigue (11.9%) and pain in combination with function
(13.0%) were the most common patterns of response; very
few patients (1.6%) reported improvement in fatigue plus
function in the absence of improvement in pain.
An alternative way of looking at PRO reporting patterns in
patients with a therapeutic response at month 12 is
presented in Figure 2. For each significant PRO, this figure
illustrates the proportions of patients with a response in that
PRO alone and with responses in multiple PROs. Although
it was not uncommon for patients to experience a significant
improvement in pain alone (20.9% of patients who reported
an improvement in pain did not have corresponding
Table 1. Demographic data and disease characteristics of the discovery and treatment cohorts*
Discovery cohort during stable











Age, years 54.3 6 12.6 55.3 6 12.6 55.8 6 12.6 56.3 6 12.6 54.6 6 12.8 55.6 6 12.8
Females, % 77.9 77.9 77.9 77.9 77.4 77.4
Disease duration, years 11.4 6 9.5 12.4 6 9.5 12.9 6 9.5 13.4 6 9.5 11.7 6 9.2 12.7 6 9.2
Tender joint count 9.7 6 7.2 3.2 6 4.8 3.5 6 5.0 3.1 6 4.8 12.6 6 7.2 5.0 6 6.0
Swollen joint count 7.2 6 5.9 2.1 6 3.5 2.1 6 3.4 2.1 6 3.6 9.7 6 6.3 3.5 6 4.5
CRP, mg/liter 17.3 6 33.7 5.7 6 11.0 6.2 6 11.4 5.5 6 10.3 32.2 6 57.1 15.4 6 33.6
ESR, mm/hour 29.8 6 21.6 19.6 6 17.1 19.6 6 17.1 20.3 6 18.2 33.8 6 22.6 22.6 6 18.6
PGA 5.9 6 2.0 3.7 6 2.0 3.7 6 2.0 3.7 6 2.1 6.6 6 1.9 4.3 6 2.1
MDGA 6.3 6 1.9 2.7 6 1.7 2.7 6 1.8 2.6 6 1.9 6.9 6 1.6 3.4 6 2.1
DAS28 5.2 6 1.3 3.3 6 1.3 3.3 6 1.4 3.3 6 1.4 5.9 6 1.2 3.9 6 1.5
% remaining function (FFbH score) 64.3 6 22.2 74.4 6 21.3 73.6 6 22.3 73.4 6 22.3 58.8 6 23.1 68.3 6 23.5
Pain 6.0 6 2.2 3.5 6 2.2 3.6 6 2.2 3.5 6 2.3 6.7 6 2.0 4.1 6 2.3
Fatigue 5.4 6 2.6 3.5 6 2.4 3.6 6 2.5 3.5 6 2.5 5.9 6 2.6 4.0 6 2.6
* Values are the mean 6 SD unless indicated otherwise. Complete data were not available for all patients. Missing data were not imputed.
CRP 5 C-reactive protein; ESR 5 erythrocyte sedimentation rate; PGA 5 patient global assessment; MDGA 5 physician global assessment;
DAS28 5 Disease Activity Score in 28 joints; dcrit 5 critical difference; FFbH 5 Funktionsfragebogen Hannover.
† Period for determination of dcrit values.
‡ Month 12 was the time point for entry into the discovery cohort on the basis of stable disease activity.
Table 2. Long-term retest reliability of PROs and the
MDGA in the discovery cohort over a period of 1 year*
Outcome No. 1-sided dcrit Reliability
Function† 644 15.91 0.942
PGA 525 2.63 0.794
Fatigue 621 3.38 0.793
Pain 626 2.99 0.774
MDGA 676 2.45 0.757
* For each outcome, analyses were performed using 3 data sets
from different time points (months 12, 18, and 24) and were lim-
ited to patients with a complete data set (data at months 12, 18,
and 24) for the outcome being evaluated. PROs 5 patient-reported
outcomes; MDGA 5 physician global assessment; PGA 5 patient
global assessment.
† As determined by the Funktionsfragebogen Hannover score.
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improvements in fatigue or function), it was quite rare for
patients to report an improvement in fatigue alone or func-
tion alone (2.4% and 4.8%, respectively, of patients with
improvements in those PROs). More commonly, patients
who showed a significant therapeutic response in fatigue
or function also had improvements in pain or in all 3 PROs.
Evaluation of PRO responses in patients not achieving a
DAS28-dcrit response. We also evaluated PRO responses
in patients who did not achieve a DAS28-dcrit response
(n 5 1,305) (Figure 1B). Of these patients, 382 (29.3%)
showed a significant improvement in pain, 196 (15.0%)
showed a significant improvement in fatigue, and 222
Figure 1. Significant responses in patient-reported outcomes (PROs) in the treatment cohort
for A, patients with a significant individual response in Disease Activity Score in 28 joints
(DAS28) (improvement $1.8) at month 12 and B, patients who did not achieve a significant
DAS28 response at month 12. The designation of “1 PRO response” includes patients with a
significant response in only 1 PRO, while “2 PRO responses” includes patients with a signif-
icant response in only 2 PROs. FFbH 5 Funktionsfragebogen Hannover questionnaire.
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(17.0%) showed a significant improvement in function
(FFbH $16). Overall, 534 (40.9%) reported a significant
improvement in at least 1 PRO (pain, fatigue, or function)
and 57 (4.4%) showed improvement in all 3 PROs; 59.1%
of patients did not experience any significant PRO re-
sponse. Pain accounted for the majority of responses in
patients with only 1 PRO response, and pain in combina-
tion with fatigue and pain in combination with function
were the most common patterns of response for patients
with 2 PRO responses.
Association between PROs and other disease activity
assessments at baseline. We evaluated the association
between PROs and other measures of disease activity in
the treatment cohort at baseline (Table 3). As might be
expected, the PRO that showed the highest correlation
with DAS28 was PGA, which is a component of DAS28.
DAS28 showed comparable correlations with function
and pain and a somewhat lower association with fatigue.
Of the PROs evaluated, pain showed the highest correla-
tion with PGA. The MDGA was moderately correlated
with DAS28, PGA, and pain, but had lower associations
with fatigue and function.
DISCUSSION
The findings reported here provide further validation for
the use of statistically based individual improvements to
evaluate changes in relevant outcomes during therapy and
offer insights into PRO improvements that occur in
patients with a DAS28-based therapeutic response. Our
study also supports the critical role of pain in influencing
patient-reported evaluations of disease activity, and sug-
gests that improved pain management should be explored
in patients who report high disease activity despite favor-
able changes in objective measures.
Figure 2. In-depth analysis of significant responses in patient-reported outcomes (PROs) in
patients in the treatment cohort with a significant individual response in Disease Activity
Score in 28 joints (improvement $1.8) at month 12 (n 5 1,483). For each significant PRO
response, the proportions of patients with a response in that PRO alone and with responses
in multiple PROs are shown. FFbH 5 Funktionsfragebogen Hannover questionnaire.
Table 3. Pearson’s correlation coefficients for PROs and additional measures of disease
activity at baseline in the treatment cohort (n 5 2,788)*
DAS28 Function† Fatigue Pain PGA MDGA
DAS28 1.00 20.41 0.29 0.42 0.49 0.52
Function† 1.00 20.48 20.51 20.53 20.31
Fatigue 1.00 0.58 0.59 0.28
Pain 1.00 0.79 0.41
PGA 1.00 0.46
MDGA 1.00
* The negative correlations observed with function are due to a difference in the direction of the
scales; higher function scores indicate improved function, whereas for the other measures lower scores
indicate improved outcomes. PROs 5 patient-reported outcomes; DAS28 5 Disease Activity Score in 28
joints; PGA 5 patient global assessment; MDGA 5 physician global assessment.
† As determined by the Funktionsfragebogen Hannover score.
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All of the outcomes examined in this study showed
excellent long-term test–retest reliability in RA patients
on constant therapy. The PROs had reliability coefficients
only slightly lower than the reliability coefficient of
DAS28 (0.757–0.793 versus 0.826); these reliability
coefficients compare favorably with values reported for
other clinical parameters such as heart rate (0.44) or blood
pressure (0.45–0.57) (15), indicating that PROs are valid
and reproducible measures of patient status.
Despite the high reliability coefficients of PROs, a size-
able change was required to achieve a significant response
outside the range of normal variation. For pain and
fatigue, both of which were measured on scales ranging
from 0 to 10, a decrease of 3 and 4 points, respectively,
was required for a statistically significant improvement.
For function, which was measured by the FFbH question-
naire on a scale ranging from 0 to 100, a change of 16
points was required; this was slightly lower than the dcrit
value of 18 points determined previously in a smaller
cohort of patients (4). Accordingly, these measures
required a change from baseline representing approxi-
mately 20% to 40% of the full measurement scale. The
level of change required for a significant improvement
should be kept in mind by clinicians when evaluating
alterations in PROs.
Other studies with different methodologies have
reported various magnitudes for changes required for rele-
vant changes in PROs in patients with RA. For pain mea-
sured on a 10-point visual analog scale (VAS), MCIDs of
0.5 (16) to 1.19 (17) and a short-term SDD of 1.63 (18) have
been reported. For fatigue measured on a 10-point VAS,
an MCID of 1.0 (19) and an SDD of 3.23 (18) have been
reported. Studies using statistically based measures to
determine values that exceed random variation, such as
SDD or reliable change index, consistently report higher
values than those that report MCID. This is best illustrated
by a study of fatigue in patients with RA that reported
both MCID and reliable change index (7). The MCID for
improvement in fatigue in this study was 0.82 to 1.12,
while the reliable change index was 3.47. The fact that the
MCID falls well within the range of random variation as
determined in this study calls into question the utility of
MCID in assessing patient responses, and suggests that
this methodology may not be optimal for long-term
assessments of changes in PROs. Our methodology differs
from those used to determine SDD or the reliability change
index in that data for test–retest reliability are obtained
over 1 year, rather than over hours or days as for these
other statistically based tests. In clinical practice, patients
with RA are seen every 3 to 6 months, so our methodology
more closely reflects routine care.
In correlation analyses, PROs were found to be moder-
ately correlated with DAS28 (Pearson’s r 5 0.32–0.42).
The lack of a stronger correlation suggests that PROs
reflect additional facets of disease activity that are not
included in clinical evaluations. Other studies have also
found that PROs are to some degree independent of clini-
cal measures of disease activity (20,21). For instance,
Kievit et al (20) reported that during routine treatment in
patients with RA, self-reported PGA improved over time
regardless of changes in DAS28, indicating that patients’
perceptions of health are not always in line with objective
disease activity assessments.
In this study, pain was the PRO most highly correlated
with PGA (Pearson’s r 5 0.79). Khan et al (22) also found
that pain is the most important determinant of PGA; in
their study, pain explained approximately 20% of the var-
iance in PGA scores, while fatigue, the second most
important determinant, explained approximately 6% of
the variance. Pain is also the most significant factor con-
tributing to discordancy between PGAs and MDGAs
(22,23). Together, these findings suggest that pain should
be given greater consideration when evaluating patients
with RA, as this PRO has a significant impact on global
well-being.
The key role played by pain was further revealed in our
analyses of significant individual PRO responses occur-
ring in patients with a therapeutic response at month 12
as assessed by DAS28-dcrit (improvement from baseline of
at least 1.8 points) (4). More than two-thirds of patients
with a DAS28 response also reported a significant
improvement in pain, either alone or in combination with
another PRO. In contrast, fewer than 40% of patients expe-
rienced improvements in fatigue or function; improve-
ments in those PROs were typically accompanied by an
improvement in pain as well.
In the present study, fatigue was not as dominant a fac-
tor as pain, although it was identified as the most critical
PRO in a study by Minnock et al (24). Our study suggests
that fatigue is not well represented in physician-based
evaluations, such as the DAS28 or MDGA, but is an impor-
tant component of a patient’s self-perceived well-being as
indicated by its correlation with PGA scores. A recent
study found that the fatigue experienced by patients with
RA is associated with RA disease activity, poor sleep qual-
ity, depression, and obesity (25); accordingly, improve-
ments in disease activity alone may not be sufficient to
decrease a patient’s overall fatigue. Of the 3 PROs we eval-
uated, fatigue was the least likely to improve. Other stud-
ies have also found that fatigue is resistant to
improvement during therapy (26,27). Nevertheless, 38.5%
of patients who remained on therapy in our study did
experience a significant response in fatigue after 12
months of adalimumab treatment, in agreement with other
studies of the effect of anti-TNF agents, including adalim-
umab, on fatigue (28,29).
An important aspect of the current study is its relevance
to the appropriate management of patients. In the cohort
of patients initiating adalimumab therapy (treatment
cohort), analyses of DAS28 and PRO responses allowed
the identification of 3 groups of patients: 1) patients who
were performing well with respect to both objective
(DAS28) and subjective (PRO) measures, 2) patients who
did not achieve a DAS28 response, but who had PRO
responses, and 3) patients who achieved a DAS28
response, but not a PRO response. These 3 categories have
significant implications with respect to treatment. For the
first category, no change in RA treatment is required. In
contrast, a change in RA treatment should be considered
for patients in the second category. The third category
poses the most difficult clinical dilemma. For these
patients, additional analyses may be required to
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differentiate between pain or fatigue related to RA and
those due to other comorbidities, such as osteoarthritis or
depression.
The findings reported here provide further support for
the use of statistically derived, individual improvement
criteria in the assessment of therapeutic response. As
reported previously (4), this measure of response is clearly
distinguishable from random variations in disease activity
and is robust over time. Approximately three-fourths of
patients with a DAS28 response had a significant improve-
ment in pain, function, or fatigue, and more than 20% had
a response in all 3 PROs, indicating that therapeutic
responses as assessed by the DAS28-dcrit are associated
with improvements in PROs in the majority of patients. In
contrast, of the patients who did not achieve a DAS28-dcrit
response at month 12, 59% had no significant PRO
responses, and significant improvements in all 3 PROs
occurred in only 4%.
Our findings may aid clinicians in informing patients of
the typical outcomes achieved during anti-TNF therapy
and in managing treatment expectations. In addition, the
results of this study suggest that clinicians should con-
sider evaluating PROs in patients who report disease
activity despite objective improvements, or introducing
PRO-based assessments, such as the Routine Assessment
of Patient Index Data 3, which includes patient-reported
physical function, pain, and global assessment (30) into
routine clinical practice. Particular attention should be
paid to self-reported pain, as pain appears to play a key
role in patient perceptions of overall well-being.
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